A meta-analysis, published in the The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients age
Abstract T2DM (Type 2 diabetes) is a complex, chronic disease characterized as insulin resistance and islet -cell dysfunction
Hormones, metabolism, stress, sleep it all adds up
The medication's dual mechanism addresses both hyperglycemia and excess weight, potentially improving outcomes in this complex patient population
Increased activity of an enzyme called glucose-6-phosphatase contributes to excessive gluconeogenesis (and glycogenolysis) in diabetics
The mechanism for immune system modulation is not yet totally proved